Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Physician Experience Predicts HIV-Related Mortality

September 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

SEATTLE-The number of HIV-infected patients that a physician has treated independently predicts HIV-related mortality in patients starting anti-retroviral therapy for the first time, Robert S. Hogg, PhD, said at the 9th Conference on Retroviruses and Opportunistic Infections (abstract 749W).

SEATTLE—The number of HIV-infected patients that a physician has treated independently predicts HIV-related mortality in patients starting anti-retroviral therapy for the first time,
Robert S. Hogg, PhD, said at the 9th Conference on Retroviruses and Opportunistic Infections (abstract 749W).

Dr. Hogg is program director of population health, British Columbia Centre for Excellence in HIV/AIDS, and associate professor of health care and epidemiology, University of British Columbia, Vancouver.

Dr. Hogg and his colleagues analyzed determinants of HIV-related and all-cause mortality in 1,219 HIV-infected, antiretroviral-naïve patients who were first prescribed triple-drug therapy between August 1996 and September 1999. Data for the patients and their approximately 100 treating physicians were obtained from the database of the British Columbia HIV/AIDS Drug Treatment Program.

Physician experience was assessed from the cumulative number of HIV-infected patients treated and was classified as above or below first quartile. Adherence to therapy was expressed as the number of months of medication dispensed divided by the number of months of follow-up during the first year of therapy, and was classified as intermittent if the value was less than 75%.

During an approximate 30-month follow-up, the rates of HIV-related and all-cause mortality were 6.7% and 8.5%, respectively. All of the non-HIV-related deaths were either suicides or accidental drug overdoses. At the start of the study, the median number of HIV-infected patients previously treated by the physicians was 47 (interquartile range, 7 to 133).

In multivariate analysis of HIV-related mortality, the risk of death was significantly decreased with physician experience above the first quartile (risk ratio, 0.54) and significantly increased with intermittent adherence (risk ratio, 3.83) and CD4 cell count below 200/µL (risk ratios at 50 to 199/µL and less than 50/µL, 3.61 and 7.29, respectively).

In multivariate analysis of all-cause mortality, the risk of death was significantly increased with intermittent adherence (risk ratio, 3.19) and CD4 cell count below 200/µL (risk ratios at 50 to 199/µL and less than 50/µL, 2.25 and 4.96, respectively). However, physician experience was not a significant predictor of all-cause mortality.

"The lack of an association between physician experience and all-cause mortality likely relates to confounding with unmeasured sociodemographic characteristics as well as to the sudden nature of accidental and overdose deaths," Dr. Hogg noted.

Use of protease inhibitors, a diagnosis of AIDS before enrollment, and a baseline plasma viral RNA level greater than 100,000 copies/mL were not significant predictors of either HIV-related or all-cause mortality in multivariate analysis.

The findings identify physician experience, intermittent adherence, and CD4 cell count as strong determinants of mortality in HIV-infected patients in the general population who are starting anti-retroviral therapy, Dr. Hogg said.

"Clearly, researchers must be cognizant of relationships like these prior to building models of prognostic factors associated with disease progression," he concluded.

Articles in this issue

Tumor-Specific Idiotype Vaccines Promising in B-Cell Lymphomas
Childhood Survivors May Not Know Their Past Rx
Pemetrexed/Gemcitabine Promising in Advanced Pancreatic Cancer
Physician Experience Predicts HIV-Related Mortality
Preliminary Phase III Results for Provenge Vaccine in Prostate Cancer
Eloxatin With 5-FU/LV Approved for Recurrent Colon Cancer
Comprehensive Geriatric Evaluations Improve Care
Nordion’s Monte Carlo Dose Calculation Software Approved
No Strong Link Between Breast Cancer Risk and Pollutants
Imatinib Inactive in Sarcomas That Lack C-KIT/PDGF
Task Force Recommends Screening for All Age 50 and Over
No Link Between Breast Cancer Risk and Pollutants
NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials
Medicare Puts PET for Thyroid Cancer, Soft Tissue Sarcoma on Hold
Cranial Radiotherapy for Childhood ALL Linked to Adult Obesity
Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Related Content
Advertisement

Regarding safety, the toxicity profile of the pembrolizumab plus belzutifan combination was consistent with what has been observed in previously reported trials.

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Tim Cortese
October 29th 2025
Article

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

Russ Conroy
October 29th 2025
Article

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

Roman Fabbricatore
October 28th 2025
Article

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.


SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

Ariana Pelosci
October 28th 2025
Article

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

Related Content
Advertisement

Regarding safety, the toxicity profile of the pembrolizumab plus belzutifan combination was consistent with what has been observed in previously reported trials.

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Tim Cortese
October 29th 2025
Article

Pembrolizumab plus belzutifan is the first combination therapy to improve DFS vs pembrolizumab monotherapy in the adjuvant treatment of those with RCC.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

Russ Conroy
October 29th 2025
Article

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.


“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.


The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

Roman Fabbricatore
October 28th 2025
Article

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.


SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

Ariana Pelosci
October 28th 2025
Article

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.